loading...| Preferred Name |
Paritaprevir |
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C123879 |
| CAS_Registry |
1216941-48-8 |
| code |
C123879 |
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 |
| Contributing_Source |
CTRP FDA |
| DEFINITION |
An orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with potential activity against HCV genotype 1. Upon administration, paritaprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells. NS3, a serine protease, is essential for the proteolytic cleavage of multiple sites within the HCV polyprotein and plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, and infection is associated with the development of hepatocellular carcinoma (HCC). |
| Display_Name |
Paritaprevir |
| FDA_UNII_Code |
OU2YM37K86 |
| FULL_SYN |
(2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-{[(5-methyl-2-pyrazinyl)carbonyl]amino}-5,16-dioxo-2-(6-phenanthridinyloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo [1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide ABT450 ABT-450 Veruprevir ABT 450 |
| label |
Paritaprevir |
| Preferred_Name |
Paritaprevir |
| prefixIRI |
C123879 |
| prefLabel |
Paritaprevir |
| Semantic_Type |
Pharmacologic Substance |
| subClassOf |